Immatics (NASDAQ:IMTX - Get Free Report) shares reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $5.73 and last traded at $5.75, with a volume of 695395 shares. The stock had previously closed at $5.97.
Analyst Ratings Changes
A number of research firms recently issued reports on IMTX. Bank of America lowered their target price on shares of Immatics from $16.00 to $15.00 and set a "buy" rating for the company in a report on Tuesday, November 19th. The Goldman Sachs Group upgraded Immatics to a "strong-buy" rating in a report on Monday, November 25th. Finally, Piper Sandler assumed coverage on Immatics in a research report on Monday, October 7th. They issued an "overweight" rating and a $19.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Immatics currently has an average rating of "Buy" and a consensus target price of $16.67.
Get Our Latest Research Report on Immatics
Immatics Price Performance
The business's 50-day simple moving average is $7.51 and its two-hundred day simple moving average is $9.93. The stock has a market capitalization of $637.38 million, a price-to-earnings ratio of -8.09 and a beta of 0.77.
Institutional Trading of Immatics
A number of institutional investors have recently added to or reduced their stakes in the business. Frazier Life Sciences Management L.P. lifted its stake in shares of Immatics by 17.5% during the third quarter. Frazier Life Sciences Management L.P. now owns 1,354,711 shares of the company's stock worth $15,457,000 after purchasing an additional 202,255 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Immatics by 1.5% during the 3rd quarter. Wellington Management Group LLP now owns 9,681,183 shares of the company's stock valued at $110,462,000 after buying an additional 144,549 shares during the period. Texas Capital Bank Wealth Management Services Inc acquired a new position in Immatics during the 3rd quarter worth approximately $114,000. State Street Corp boosted its holdings in Immatics by 11.2% in the 3rd quarter. State Street Corp now owns 225,202 shares of the company's stock worth $2,570,000 after acquiring an additional 22,710 shares during the period. Finally, Quarry LP boosted its holdings in Immatics by 29.4% in the 3rd quarter. Quarry LP now owns 11,000 shares of the company's stock worth $126,000 after acquiring an additional 2,500 shares during the period. 64.41% of the stock is owned by hedge funds and other institutional investors.
About Immatics
(
Get Free Report)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Recommended Stories
Before you consider Immatics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immatics wasn't on the list.
While Immatics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
